Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer
- PMID: 21908097
- DOI: 10.1016/j.eururo.2011.08.041
Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer
Abstract
Background: Some evidence indicates that androgen-deprivation therapy (ADT) increases the risk of diabetes and cardiovascular disease. To date, few studies have investigated whether this therapy also increases the risk of cerebrovascular events.
Objective: To determine whether different types of ADT increase the risk of stroke/transient ischaemic attacks (TIAs) in patients with prostate cancer.
Design, setting, and participants: We conducted a population-based cohort study using a nested case-control analysis within the United Kingdom's General Practice Research Database population. The cohort included all patients at least 40 yr of age newly diagnosed with prostate cancer between January 1, 1988, and December 31, 2008, and followed until December 31, 2009. Cases consisted of those who experienced a first-ever stroke/TIA during follow-up. Up to 10 controls were matched to each case on age, year of cohort entry, and duration of follow-up.
Measurements: Adjusted rate ratios (RRs) of stroke/TIA associated with the use of different ADTs (gonadotropin-releasing hormone [GnRH] agonists, oral antiandrogens, combined androgen blockade, bilateral orchiectomy, and others) were estimated using conditional logistic regression.
Results and limitations: The cohort included 22 310 patients with prostate cancer, followed for a mean of 3.9 yr, where 938 patients experienced a first-ever stroke/TIA (rate: 10.7 per 1000/yr). Compared with nonusers of ADT, current users of GnRH agonists (adjusted RR: 1.18; 95% confidence interval [CI], 1.00-1.39), oral antiandrogens (adjusted RR: 1.47; 95% CI, 1.08-2.01), and those who underwent bilateral orchiectomy (adjusted RR: 1.77; 95% CI, 1.25-2.39) were at an increased risk of stroke/TIA. No statistically significant increased risks were observed for patients on combined androgen blockade and other ADTs, but the small numbers do not rule out a possible association.
Conclusions: The results of this large population-based study provide additional evidence that different forms of ADT may increase the risk of stroke/TIA.
Copyright © 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Comment in
-
Prostate cancer: cardiovascular risk and androgen deprivation therapy.Nat Rev Urol. 2012 Jan 10;9(2):61. doi: 10.1038/nrurol.2011.229. Nat Rev Urol. 2012. PMID: 22231292 No abstract available.
Similar articles
-
Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.JAMA. 2013 Jul 17;310(3):289-96. doi: 10.1001/jama.2013.8638. JAMA. 2013. PMID: 23860987
-
Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.Osteoporos Int. 2015 Sep;26(9):2281-90. doi: 10.1007/s00198-015-3135-9. Epub 2015 May 20. Osteoporos Int. 2015. PMID: 25990353
-
Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study.Eur Urol. 2014 Apr;65(4):704-9. doi: 10.1016/j.eururo.2013.02.002. Epub 2013 Feb 12. Eur Urol. 2014. PMID: 23433805
-
Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.Eur Urol. 2015 Sep;68(3):386-96. doi: 10.1016/j.eururo.2014.11.039. Epub 2014 Dec 5. Eur Urol. 2015. PMID: 25484142 Review.
-
Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis.Prostate Cancer Prostatic Dis. 2018 Nov;21(4):451-460. doi: 10.1038/s41391-018-0059-4. Epub 2018 Jul 9. Prostate Cancer Prostatic Dis. 2018. PMID: 29988099
Cited by
-
Changes in Renal Function of Patients With Prostate Cancer: Focus on Androgen Deprivation Therapy.Cancer Diagn Progn. 2022 Nov 3;2(6):686-690. doi: 10.21873/cdp.10160. eCollection 2022 Nov-Dec. Cancer Diagn Progn. 2022. PMID: 36340454 Free PMC article.
-
Radical radiotherapy for high-risk prostate cancer in older men.Oncologist. 2012;17 Suppl 1(Suppl 1):9-15. doi: 10.1634/theoncologist.2012-S1-09. Oncologist. 2012. PMID: 23015680 Free PMC article.
-
Validity of the recorded codes of gonadotropin-releasing hormone agonist treatment and orchiectomies in the Danish National Patient Registry.Clin Epidemiol. 2012;4:145-9. doi: 10.2147/CLEP.S32313. Epub 2012 Jun 18. Clin Epidemiol. 2012. PMID: 22942650 Free PMC article.
-
Adverse effects of androgen deprivation therapy in men with prostate cancer: a focus on metabolic and cardiovascular complications.Asian J Androl. 2012 Mar;14(2):222-5. doi: 10.1038/aja.2011.109. Epub 2012 Feb 20. Asian J Androl. 2012. PMID: 22343494 Free PMC article. Review.
-
Cancer Therapy-Related Cardiac Dysfunction in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy.J Am Heart Assoc. 2023 Oct 3;12(19):e030447. doi: 10.1161/JAHA.123.030447. Epub 2023 Sep 26. J Am Heart Assoc. 2023. PMID: 37750600 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical